Corient Private Wealth
DFTX

Corient Private Wealth’s Definium Therapeutics DFTX Stock Holding History

Corient Private Wealth’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Buy
+24,391
New +$603K ﹤0.01% 1730

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Corient Private Wealth's DFTX Position: Q2 2026 in Review

Corient Private Wealth opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 24,391 shares worth $1.15M. The stake represents ﹤0.01% of the portfolio and ranks #1730 among its holdings.

361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Corient Private Wealth held 24,391 shares of Definium Therapeutics worth $1.15M as of Q2 2026.
  • Definium Therapeutics was a new Corient Private Wealth position in Q2 2026.
  • Definium Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1730 holding.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.